Egypt Diabetes Drugs Market Size
|Study Period||2017- 2028|
|Base Year For Estimation||2022|
|Forecast Data Period||2023 - 2028|
|Market Size (2023)||USD 402.58 Million|
|Market Size (2028)||USD 466.70 Million|
|CAGR (2023 - 2028)||3.00 %|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Egypt Diabetes Drugs Market Analysis
The Egypt Diabetes Drugs Market size is expected to grow from USD 402.58 million in 2023 to USD 466.70 million by 2028, at a CAGR of 3% during the forecast period (2023-2028).
The market is estimated to reach a value of more than USD 730 million by 2027.
The COVID-19 pandemic positively impacted the Diabetes Drugs market growth in Egypt. Patients with diabetes, infected with COVID-19 may experience elevated blood glucose, abnormal glucose variability, and diabetic complications. The prevalence of diabetes in people with COVID-19 caused a significant increase in severity and mortality of COVID-19 in people with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), especially in association with poor glycemic control. While new-onset hyperglycemia and new-onset diabetes (both T1DM and T2DM) have been increasingly recognized in the context of COVID-19 and have been associated with worse outcomes. To avoid aggravation, a patient's blood glucose should be monitored and managed regularly.
Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs are commonly used to manage diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic.
Egypt is the ninth country in terms of Diabetes prevalence worldwide. Currently, as per IDF, about 18.4% of the adult population in Egypt has diabetes. More than 11% of the Egyptian population suffers from diagnosed Type-2 diabetes according to Egypt Youth Association for Health Development. 73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Diabetes poses an emerging healthcare burden across the country and is one of the leading causes of premature death, morbidity, and loss of economic growth.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Egypt Diabetes Drugs Industry Segmentation
Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Egypt Diabetes Drugs Market is segmented into drugs (insulin drugs (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, and biosimilar insulins), oral anti-diabetic drugs (Biguanides, Alpha-Glucosidase inhibitors, Dopamine D2 receptor agonist, SGLT-2 inhibitors, DPP-4 inhibitors, Sulfonylureas, and Meglitinides), non-insulin injectable drugs (GLP-1 receptor agonists and Amylin Analogue), and combination drugs (insulin combinations and oral combinations)). The report offers the value (in USD million) and volume (in units million) for the above segments.
|Oral Anti-diabetic drugs|
|Non-Insulin Injectable drugs|
Egypt Diabetes Drugs Market Trends
The oral anti-diabetic drugs segment holds the highest market share in the Egypt Diabetes Drugs Market in the current year
The oral anti-diabetic drugs segment holds the highest market share of about 88.8% in the Egypt Diabetes Drugs Market in the current year.
Oral Anti-Diabetic Drugs are available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in treating type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. Anti-diabetic drugs help diabetes patients control their condition and lower the risk of diabetes complications. People with diabetes may need to take anti-diabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost. So they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.
In July 2022, Zydus Lifesciences announced that it had received final approval to market Empagliflozin and Metformin Hydrochloride tablets in multiple strengths. Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. They are also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.
The Egyptian Government launched the “100 million Seha” initiative, which seeks to screen Egyptians for non-communicable diseases like diabetes. Various healthcare companies announced their collaboration with the Egypt Ministry of Health to promote the initiative. Such initiatives are expected to create awareness among the people regarding monitoring and controlling diabetes, thereby enhancing the market prospects in the coming years.
To understand key trends, Download Sample Report
Metformin is expected to dominate the Egypt Diabetes Drugs Market over the forecast period
Metformin is expected to dominate the Egypt Diabetes Drugs Market and register a CAGR of around 1.5% over the forecast period.
Biguanides are a class of medications used to treat type 2 diabetes. They work by reducing the production of glucose that occurs during digestion. Metformin is the only biguanide currently available in most countries for treating diabetes. Glucophage (metformin) and Glucophage XR (metformin extended release) are well-known brand names for these drugs. Others include Fortamet, Glumetza, and Riomet. Metformin is also available in combination with several other types of diabetes medications, such as sulfonylureas.
Diabetes reduces lifespan, and people with the disease are likely to experience blindness and be hospitalized for amputations, kidney failure, heart attacks, strokes, and heart failure. Metformin is the first-line choice for the management of hyperglycemia in T2DM. Besides being an important glucose-lowering agent, metformin also includes significant anti-inflammatory properties. Other options must be considered when metformin is contraindicated or not tolerated or when treatment goals are not achieved after three months of use at the maximum tolerated dose. Dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 agonists are generally used to supplement treatment with metformin.
In Egypt, the social level plays an important role in patients’ access to health care. The number of healthcare centers, hospitals, and pharmacies is very low in rural areas compared to big cities and urban areas. The financial level is a major determinant of people’s access to health care, as the salaries of most employees in Egypt are not enough to afford their monthly diabetes supplies. For students and school children with type 1 diabetes, the National Health Insurance System covers insulin, and the student pays nothing for NPH, mixed and short-acting insulins, and only 60% of the price of other types of insulin, which are usually unavailable in the pharmacies of the National Health Insurance System. However, the government is working in the direction of improving the access of patients through various initiatives.
Egypt Diabetes Drugs Industry Overview
The Egypt Diabetes Drugs Market is moderately consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, and other generic players holding a presence in the region. A major share of the market is held by manufacturers concomitant with strategy-based M&A operations and constantly entering the market to generate new revenue streams and boost existing ones.
Egypt Diabetes Drugs Market Leaders
Novo Nordisk A/S
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
Egypt Diabetes Drugs Market News
- October 2022: The Ministry of Industry and Advanced Technology announced the signing of a pair of memoranda of understanding worth AED 260 million (USD 70.8 million) between major pharmaceutical and medical device companies in the UAE. The partnerships align with the National Strategy for Industry and Advanced Technology and the ICV Program. It aims to attract investors and manufacturers to the UAE’s pharmaceutical and medical equipment sectors. Under a separate MoU, PureHealth, and Gulf Pharmaceutical Industries Company will establish the first factory in the Middle East to produce Glargine to treat diabetes.
- June 2022: Gulf Pharmaceutical Industries (Julphar) and Hangzhou Zhongmei Huadong Pharmaceutical Co. announced strategic cooperation to develop, manufacture, and commercialize Liraglutide (including both indications of diabetes and obesity) in 17 countries in the Middle East and North Africa region, including the UAE.
Egypt Diabetes Drugs Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1.1 Basal or Long Acting Insulins
188.8.131.52 Lantus (Insulin Glargine)
184.108.40.206 Levemir (Insulin Detemir)
220.127.116.11 Toujeo (Insulin Glargine)
18.104.22.168 Tresiba (Insulin Degludec)
22.214.171.124 Basaglar (Insulin Glargine)
5.1.2 Bolus or Fast Acting Insulins
126.96.36.199 NovoRapid/Novolog (Insulin Aspart)
188.8.131.52 Humalog (Insulin Lispro)
184.108.40.206 Apidra (Insulin Glulisine)
5.1.3 Traditional Human Insulins
5.1.4 Biosimilar Insulins
220.127.116.11 Insulin Glargine Biosimilars
18.104.22.168 Human Insulin Biosimilars
5.2 Oral Anti-diabetic drugs
5.2.2 Alpha-Glucosidase Inhibitors
22.214.171.124 Alpha-Glucosidase Inhibitors
5.2.3 Dopamine D2 receptor agonist
5.2.4 SGLT-2 inhibitors
126.96.36.199 Invokana (Canagliflozin)
188.8.131.52 Jardiance (Empagliflozin)
184.108.40.206 Farxiga/Forxiga (Dapagliflozin)
220.127.116.11 Suglat (Ipragliflozin)
5.2.5 DPP-4 inhibitors
18.104.22.168 Onglyza (Saxagliptin)
22.214.171.124 Tradjenta (Linagliptin)
126.96.36.199 Galvus (Vildagliptin)
5.3 Non-Insulin Injectable drugs
5.3.1 GLP-1 receptor agonists
188.8.131.52 Victoza (Liraglutide)
184.108.40.206 Byetta (Exenatide)
220.127.116.11 Bydureon (Exenatide)
18.104.22.168 Trulicity (Dulaglutide)
22.214.171.124 Lyxumia (Lixisenatide)
5.3.2 Amylin Analogue
126.96.36.199 Symlin (Pramlintide)
5.4 Combination drugs
5.4.1 Insulin combinations
188.8.131.52 NovoMix (Biphasic Insulin Aspart)
184.108.40.206 Ryzodeg (Insulin Degludec and Insulin Aspart)
220.127.116.11 Xultophy (Insulin Degludec and Liraglutide)
5.4.2 Oral Combinations
18.104.22.168 Janumet (Sitagliptin and Metformin)
6. MARKET INDICATORS
6.1 Type-1 Diabetic Population
6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk A/S
7.1.4 Eli Lilly
7.1.5 Janssen Pharmaceuticals
7.1.7 Boehringer Ingelheim
7.1.8 Merck and Co.
7.1.10 Bristol Myers Squibb
7.1.13 Sanofi Aventis
- *List Not Exhaustive
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk A/S
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Merck and Co.
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Egypt Diabetes Drugs Market Research FAQs
How big is the Egypt Diabetes Drugs Market?
The Egypt Diabetes Drugs Market size is expected to reach USD 402.58 million in 2023 and grow at a CAGR of 3% to reach USD 466.70 million by 2028.
What is the current Egypt Diabetes Drugs Market size?
In 2023, the Egypt Diabetes Drugs Market size is expected to reach USD 402.58 million.
Who are the key players in Egypt Diabetes Drugs Market?
AstraZeneca, Boehringer Ingelheim, Novo Nordisk A/S, Sanofi Aventis and Eli Lilly and Company are the major companies operating in the Egypt Diabetes Drugs Market.
Egypt Diabetes Drugs Industry Report
Statistics for the 2023 Egypt Diabetes Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Egypt Diabetes Drugs analysis includes a market forecast outlook to for 2023 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.